جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains clopidogrel 75,0 mg

جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains metformin hydrochloride 500,0 mg

جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 60,0 mg

جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 90,0 mg

جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains etoricoxib 120,0 mg

جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains apixaban 5,0 mg

جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - see ingredients - each tablet contains apixaban 2,5 mg

جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - capsules - see ingredients - each capsule contains dutasteride 0,5 mg

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline hydrochloride capsules are indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute rec

جنوب أفريقيا - الإنجليزية - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - #n/a - not indicated - none